Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer.
Ikesue H, Kusuda K, Satsuma Y, Nishiwaki F, Miura R, Masuda Y, Hirabatake M, Muroi N, Fujimoto D, Morimoto T, Tomii K, Hashida T. Ikesue H, et al. Among authors: hirabatake m. J Clin Pharm Ther. 2020 Dec;45(6):1288-1294. doi: 10.1111/jcpt.13207. Epub 2020 Jun 10. J Clin Pharm Ther. 2020. PMID: 32519774 Free PMC article.
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T. Ikesue H, et al. Among authors: hirabatake m. Cancer Chemother Pharmacol. 2021 Jun;87(6):871-877. doi: 10.1007/s00280-021-04262-w. Epub 2021 Mar 31. Cancer Chemother Pharmacol. 2021. PMID: 33791853 Free PMC article.
Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.
Ikesue H, Yamaoka K, Matsumoto A, Hirabatake M, Muroi N, Yamasaki T, Kawakita M, Hashida T. Ikesue H, et al. Among authors: hirabatake m. Cancer Chemother Pharmacol. 2022 Jun;89(6):833-838. doi: 10.1007/s00280-022-04408-4. Epub 2022 Mar 7. Cancer Chemother Pharmacol. 2022. PMID: 35254504 Free PMC article.
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T. Ikesue H, et al. Among authors: hirabatake m. Support Care Cancer. 2021 Aug;29(8):4763-4772. doi: 10.1007/s00520-021-06018-x. Epub 2021 Feb 1. Support Care Cancer. 2021. PMID: 33527228 Free PMC article.
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T. Ikesue H, et al. Among authors: hirabatake m. Support Care Cancer. 2022 Mar;30(3):2341-2348. doi: 10.1007/s00520-021-06634-7. Epub 2021 Nov 5. Support Care Cancer. 2022. PMID: 34738163 Free PMC article.
22 results